Advertisement

Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study

Published:August 02, 2022DOI:https://doi.org/10.1016/j.dld.2022.07.004

      Abstract

      Introduction

      Clinical data on the efficacy and safety of non-medical switch between adalimumab(ADA) biosimilars are limited.

      Aims

      The aim of this study was to evaluate medium-term clinical efficacy, drug sustainability and safety comparing non-medical switches from the originator to biosimilar ADA, and between ADA biosimilars.

      Methods

      276 consecutive patients on maintenance ADA therapy (n = 205 Crohn's disease, n = 71 ulcerative colitis) were included. Data on clinical efficacy, biomarkers and adverse events were collected at four time points: 8–12 weeks prior switch, at baseline/switch, 8–12 weeks and 20–24 weeks after switch. Drug survival was evaluated after a median 40(IQR:35–42) weeks follow-up.

      Results

      A total 174 patients underwent a non-medical switch from the originator to a biosimilar, and 102 patients had a biosimilar-to-biosimilar switch. No significant difference was found in clinical remission rates at any time point in patients switching from originator to biosimilar(87.3%/88.5%/86.5%/85.7%) or biosimilar to biosimilar(74.5%/78.4%/85.3%/79.8%). Mean C-reactive protein levels remained unchanged in both cohorts(p = 0.856 and p = 0.525). Drug survival was similar between the two cohorts with a probability of 91.6%(SE: 2.2) and 87.0%(SE:3.4) to stay on drug after 40 weeks(log-rank:0.96; p = 0.327). Five cases of injection related adverse events were reported.

      Conclusion

      Clinical benefit was sustained following non-medical switch from originator to biosimilar, or between biosimilars in adalimumab treated IBD patients.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • van der Valk M.E.
        • Mangen M.J.
        • Leenders M.
        • et al.
        COIN study group and the dutch initiative on crohn and colitis. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
        Gut. Jan 2014; 63: 72-79
      1. European Medicines Agency recommends approval of first two monoclonal-antibody biosimilars. 2013. Available at: https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-approval-first-two-monoclonal-antibody-biosimilars Accessed: January 16, 2022

      2. FDA approves Inflectra, a biosimilar to Remicade. 2016. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-inflectra-biosimilar-remicade Accessed: January 16, 2022

        • Cohen H.
        • Beydoun D.
        • Chien D.
        • et al.
        Awareness, knowledge, and perceptions of biosimilars among specialty physicians.
        Adv Ther. Jan 2017; 33: 2160-2172
        • Ye B.D.
        • Pesegova M.
        • Alexeeva O.
        • et al.
        Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
        Lancet. Apr 27 2019; 393: 1699-1707
        • Jørgensen K.K.
        • Olsen I.C.
        • Goll G.L.
        • NOR-SWITCH study group
        Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
        Lancet. Jun 2017; 389: 2304-2316
        • Komaki Y.
        • Yamada A.
        • Komaki F.
        • et al.
        Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
        Aliment Pharmacol Ther. Apr 2017; 45: 1043-1057
        • Danese S.
        • Fiorino G.
        • Raine T.
        • et al.
        ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update.
        J Crohns Colitis. Jan 2017; 11: 26-34
        • Papp K.
        • Bachelez H.
        • Costanzo A.
        • et al.
        Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study.
        J Am Acad Dermatol. Jun 2017; 76: 1093-1102
        • Cohen S.
        • Genovese M.C.
        • Choy E.
        • et al.
        Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
        Ann Rheum Dis. Oct 2017; 76: 1679-1687
        • Cohen S.B.
        • Alonso-Ruiz A.
        • Klimiuk P.A.
        • et al.
        Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
        Ann Rheum Dis. Jun 2018; 77: 914-921
        • Gonczi L.
        • Gecse K.B.
        • Vegh Z.
        • et al.
        Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort.
        Inflamm Bowel Dis. Nov 2017; 23: 1908-1915
        • Ilias A.
        • Szanto K.
        • Gonczi L.
        • et al.
        Outcomes of patients with inflammatory bowel diseases switched from maintenance therapy with a biosimilar to remicade.
        Clin Gastroenterol Hepatol. Nov 2019; 17 (.e2): 2506-2513
      3. National Health Insurance Fund of Hungary – Reimbursement protocols. http://www.neak.gov.hu/felso_menu/szakmai_oldalak/finanszirozasi_protokollok Accessed: January 16, 2022

        • Satsangi J.
        • Silverberg M.S.
        • Vermeire S.
        • Colombel J.F.
        The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.
        Gut. Jun 2006; 55: 749-753
        • Burisch J.
        • Vardi H.
        • Schwartz D.
        • Epi-IBD group
        Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
        Lancet Gastroenterol Hepatol. May 2020; 5: 454-464
        • Liu J.
        • Eris T.
        • Li C.
        • et al.
        Assessing analytical similarity of proposed Amgen biosimilar ABP 501 to adalimumab.
        BioDrugs. Aug 2016; 30: 321-338
        • Tapete G.
        • Bertani L.
        • Pieraccini A.
        • et al.
        Effectiveness and safety of nonmedical switch from adalimumab originator to SB5 biosimilar in patients with inflammatory bowel diseases: twelve-month follow-up from the tablet registry.
        Inflamm Bowel Dis. Jan 5 2022; 28: 62-69
        • Lukas M.
        • Malickova K.
        • Kolar M.
        • et al.
        Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: short-term experience from a single tertiary clinical centre.
        J Crohns Colitis. Jul 30 2020; 14: 915-919
        • Cingolani L.
        • Barberio B.
        • Zingone F.
        • et al.
        Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.
        Sci Rep. May 14 2021; 11: 10368
        • Derikx L.A.A.P.
        • Dolby H.W.
        • Plevris N.
        • et al.
        Effectiveness and safety of adalimumab biosimilar SB5 in inflammatory bowel disease: outcomes in originator to SB5 switch, double biosimilar switch and bio-naïve SB5 observational cohorts.
        J Crohns Colitis. Dec 18 2021; 15: 2011-2021
        • Billioud V.
        • Sandborn W.J.
        • Peyrin-Biroulet L.
        Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.
        Am J Gastroenterol. 2011; 106: 674-684
        • Hanauer S.
        • Liedert B.
        • Balser S.
        • et al.
        Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
        Lancet Gastroenterol Hepatol. Oct 2021; 6: 816-825
        • Ribaldone D.G.
        • Tribocco E.
        • Rosso C.
        • et al.
        Switching from biosimilar to biosimilar adalimumab, including multiple switching, in Crohn's disease: a prospective study.
        J Clin Med. Jul 30 2021; 10: 3387
        • Blauvelt A.
        • Lacour J.P.
        • Fowler Jr, J.F.
        • et al.
        Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
        Br J Dermatol. Sep 2018; 179: 623-631
        • Albader F.
        • Golovics P.A.
        • Gonczi L.
        • et al.
        Therapeutic drug monitoring in inflammatory bowel disease: the dawn of reactive monitoring.
        World J Gastroenterol. Oct 7 2021; 27: 6231-6247